The chemistry of biological sulfonium compounds

S-adenosylmethionine decarboxylase from human prostate. Activation by putrescine

1. The presence of S-adenosylmethionine decarboxylase in human prostate gland is reported. A satisfactory radiochemical enzymic assay was developed and the enzyme was partially characterized. 2. Putrescine stimulates the reaction rate by up to 6-fold at pH7.5: the apparent activation constant was estimated to be 0.13mm. The stimulation is pH-dependent and a maximal effect is observed at acid pH values. 3. Putrescine activation is rather specific: other polyamines, such as spermidine and spermine, did not show any appreciable effect. 4. The apparent K(m) for the substrate is 4x10(-5)m. The calculated S-adenosylmethionine content of human prostate (0.18mumol/g wet wt. of tissue) demonstrates that the cellular amounts of sulphonium compound are saturating with respect to the enzyme. 5. The enzyme is moderately stable at 0 degrees C and is rapidly inactivated at 40 degrees C. The optimum pH is about 7.5, with one-half of the maximal activity occurring at pH6.6. 6. Several carboxy-(14)C-labelled analogues and derivatives of S-adenosylmethionine were tested as substrates. The enzyme appears to be highly specific: the replacement of the 6'-amino group of the sulphonium compound alone results in a complete loss of activity. 7. Inhibition of the enzyme activity by several carbonyl reagents suggests an involvement of either pyridoxal phosphate or pyruvate in the catalytic process. 8. The inhibitory effect of thiol reagents indicates the presence of ;essential' thiol groups.

Some mutants of Saccharomyces cerevisiae inhibited by adenoylmethionine and adenosylhomocysteine

These investigations have established the existence of a novel type of non-nutritional mutant (ai) which is inhibited in the presence of two naturally occurring cellular compounds. The inhibition is complete at an extracellular concentration at least as low as 0.05 mumole/ml of either adenosylhomocysteine or adenosylmethionine. It is suggested that adenosylhomocysteine is the true inhibitor. The ai mutants are phenotypically indistinguishable from the wild type in the absence of inhibitors. The results have shown that, if any direct effect on the methionine biosynthetic pathway exists, it is a secondary rather than the primary effect of the inhibitors. The ai mutation does not involve the loss of the adenosylmethionine (or methylmethionine): homocysteine methyltransferase. In addition, the ai mutants accumulate, maintain, and utilize adenosylmethionine and methionine in a manner similar to the parental strain. No genetic relationship could be detected between the ai-1 mutation and several different markers affecting methionine biosynthesis. The ai-1 mutation was also shown to be genetically recessive. Methionine partially reverses the inhibition caused by adenosylmethionine or adenosylhomocysteine. Neither methylmethionine nor homocysteine reversed the inhibition, which showed that the homocysteine methyltransferase cannot catalyze the synthesis of sufficient methionine under these conditions to simulate the effects of extracellularly supplied methionine. If adenine is present, methionine does not cause reversal of inhibition due to adenosylmethionine or adenosylhomocysteine. From the data presented, it is clear that the ai mutation involves some metabolic control mechanism, though the alteration does not appear to be associated primarily with the biosynthesis of methionine.